A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RES® (Regenerative Epidermal Suspension) Prepared With the RECELL® Device Compared to Standard of Care Dressings for Treatment of Partial-thickness Burns in Infants, Children and Adolescents (Aged 1-16 Years)

Status: Terminated
Location: See all (9) locations...
Intervention Type: Device, Procedure, Combination product
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 16
Healthy Volunteers: f
View:

• Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness thermal burn injury.

• The patient has a thermal burn injury that is:

‣ ≤ 30% TBSA (exclusive of superficial areas) and

⁃ ≤ 10% of the burn injury TBSA is a full-thickness burn.

• The Index Burn must be a clean partial-thickness burn injury \> or = to 160 cm2 and between 2-20% BSA (inclusive).

• The Index Burn may not cover the face, hand, foot or perineum/genitalia (Note: a patient with wounds in these areas may be enrolled but the Index Burn Area may not include these areas).

• The patient and/or guardian agrees to comply with all compulsory study procedures and visit schedule.

• The patient and/or parent/guardian agrees to abstain from any other treatment for closure of the Index Burn for the duration of the study, unless medically necessary.

• The patient and/or parent/guardian agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study.

• In the opinion of the investigator, the patient and/or parent/guardian must be able to:

‣ Understand the full nature and purpose of the study, including possible risks and adverse events,

⁃ Understand instruction, and

⁃ Provide voluntary informed written consent/assent as appropriate for study participation.

Locations
United States
Arizona
Arizona Burn Center / Valleywise Health
Phoenix
Florida
University of South Florida Tampa General Hospital
Tampa
Louisiana
University Medical Center New Orleans
New Orleans
North Carolina
University of North Carolina
Chapel Hill
Wake Forest Baptist Medical Center
Winston-salem
Pennsylvania
Saint Christopher's Hospital for Children
Philadelphia
South Carolina
Medical University of South Carolina
Charleston
Virginia
Evan Hayes Burn Center, Virginia Commonwealth University
Richmond
Washington
University of Washington Regional Burn Center at Harborview Medical Center
Seattle
Time Frame
Start Date: 2020-03-03
Completion Date: 2022-06-03
Participants
Target number of participants: 19
Treatments
Experimental: RECELL® Autologous Cell Harvesting Device
RECELL + Telfa™ Clear and Xeroform™ dressings~Conventional autografting (only when indicated)
Active_comparator: Mepilex® Ag Wound Dressing
Mepilex® Ag Wound Dressing~Conventional autografting (only when indicated)
Sponsors
Leads: Avita Medical
Collaborators: Biomedical Advanced Research and Development Authority

This content was sourced from clinicaltrials.gov

Similar Clinical Trials